ASCO Impact Report From Encuity Research Indicates Oncologists Are Likely to Shift Patient Treatment Plans
NEWTOWN, Pa., June 21, 2012 /PRNewswire/ -- Encuity Research, the market research and analytics subsidiary of Campbell Alliance, today released the results of its ASCO Impact Report, a survey of physicians attending the 2012 annual meeting of the American Society of Clinical Oncologists (ASCO). The survey was designed to evaluate the relevancy and effectiveness of company-sponsored clinical data and promotions at ASCO.
Encuity's survey results revealed that this year's event had a significant impact on the treatment plans of oncologists and hematologists in attendance—with 76% indicating that they are likely to change their patient treatment plans based on ASCO findings.
New breast cancer and prostate cancer treatment plans gained the most traction. Among the ASCO-attending physicians surveyed, 45% intend to change their breast cancer treatment plan once Genentech's T-DM1 becomes available, while 44% intend to increase their use of Johnson & Johnson's prostate cancer treatment, Zytiga®.
The majority, 86%, of ASCO-attending physicians also awarded the highest overall "presentation of information" rankings to T-DM1. This endorsement was closely followed by Zytiga®, earning "very or extremely valuable" ratings from 73% of physicians surveyed.
"It is clear that several companies delivered clinical presentation home runs at ASCO, while others did not," said Michael Turner, General Manager of Encuity Research. "The study also showed that ASCO will have a significant impact on the future behavior of physicians in attendance. This demonstrates, above all, that companies cannot afford a promotional 'swing and miss' when the stakes are so high."
The ASCO Impact Report provides an encompassing view of ASCO attendees' intent to change treatment plans, their perception of clinical information presented, and their ratings of information offered by pharmaceutical and biotech companies, including physician-deemed "up-and-comers" Seattle Genetics, Celgene, and Millennium.
This report is based on an online survey of 100 oncologists and hematologists who attended the event. In addition to custom research, Encuity provides 11 syndicated market research services, including its Physician Meeting and Event Audit. Data from this audit indicate that pharmaceutical and biotech companies spent $2.9 billion on events in the past 12 months, with 11% of their budgets going to symposia like ASCO.
For more information and to download a copy of the ASCO Impact Report, please visit http://www.encuity.com/asco.
About Encuity Research
Encuity Research is the market research and analytics subsidiary of Campbell Alliance. Encuity's team of skilled market research professionals provides answers that biopharmaceutical leaders need to make critical decisions at enterprise, portfolio, and product levels. Its services span five key areas, including custom qualitative and quantitative market research and analytics, syndicated market research, promotional message tracking, and key opinion leader (KOL) identification. For more information on Encuity and its services, please visit http://www.encuity.com.
About Campbell Alliance
Campbell Alliance is the Consulting business segment of inVentiv Health, a leading global provider of best-in-class clinical, commercial, and consulting services to companies seeking to accelerate performance. Campbell Alliance is the leading management consulting firm specializing in the pharmaceutical and biotechnology industry. The firm's clients include all of the world's top-20 pharmaceutical companies, as well as numerous emerging and midsize firms. Campbell Alliance is organized into practice areas, each specializing in a critical industry function: Brand Management, Business Development, Clinical Development, Commercial Effectiveness, Pricing and Market Access, and Medical Affairs. From its locations in New York City, Raleigh, NC, Parsippany, NJ, Los Angeles, San Francisco, Chicago, Boston, Philadelphia, Atlanta, and Zug, Switzerland, the firm serves clients throughout North America, Europe, and Japan. For more information on Campbell Alliance, please visit http://www.campbellalliance.com.
About inVentiv Health
inVentiv Health, Inc. is a leading global provider of best-in-class clinical, commercial and consulting services to companies seeking to accelerate performance. inVentiv's client roster includes more than 550 pharmaceutical, biotech and life sciences companies. With 13,000 employees in 40 countries, inVentiv rapidly transforms promising ideas into commercial reality. inVentiv Health Inc. is privately owned by inVentiv Group Holdings Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. For more information, visit http://www.inventivhealth.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause our performance to differ materially. These forward-looking statements reflect our current views about future events and are subject to risks, uncertainties and assumptions. We wish to caution readers that certain important factors may have affected and could in the future affect our actual results and could cause actual results to differ significantly from those expressed in any forward-looking statement. Such factors include, without limitation: the impact of our substantial level of indebtedness on our ability to generate sufficient cash to fulfill our obligations under our existing debt instruments or our ability to incur additional indebtedness; the impact of the consummation of any announced and future acquisitions, and any additional leverage we may incur in connection with the financing thereof, on our ratings and the ratings of our debt securities; our ability to sufficiently increase our revenues and maintain or decrease expenses and cash capital expenditures to permit us to fund our operations; our ability to continue to comply with the covenants and terms of our senior secured credit facilities and to access sufficient capital under our credit agreement or from other sources of debt or equity financing to fund our operations; the impact of any default by any of our credit providers; our ability to accurately forecast costs to be incurred in providing services under fixed price contracts; our ability to accurately forecast insurance claims within our self- insured programs; the potential impact of pricing pressures on pharmaceutical manufacturers from future healthcare reform initiatives or from changes in the reimbursement policies of third-party payers; our ability to grow our existing client relationships, obtain new clients and cross-sell our services; the potential impact of financial, economic, political and other risks, including interest rate and exchange rate risks, related to conducting business internationally; our ability to successfully operate new lines of business; our ability to manage our infrastructure and resources to support our growth; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations and integrate the acquired businesses into our operation, and the resulting synergies; the resolution of purchase price adjustment disputes in connection with our recent acquisitions and related impacts; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development of software; the potential impact of government regulation on us and on our client base; our ability to comply with all applicable laws as well as our ability to successfully implement from a timing and cost perspective any changes in applicable laws; our ability to recruit, motivate and retain qualified personnel, including sales representatives; the possibility that client agreements will be terminated or not renewed; any potential impairment of goodwill or intangible assets; consolidation in the pharmaceutical industry; changes in trends in the healthcare and pharmaceutical industries or in pharmaceutical outsourcing, including initiatives by our clients to perform services we offer internally; the impact of customer project delays and cancellations; the potential liability associated with bringing new drugs to market, including potential liability from injury to clinical trial participants; the actual impact of the adoption of certain accounting standards; and our ability to maintain technological advantages in a variety of functional areas, including sales force automation, electronic claims surveillance and patient compliance. Holders of our debt instruments are referred to reports provided to investors from time to time and the offering memorandums provided in connection with the issuance of our senior secured notes for further discussion of these risks and other factors.
Director, Public & Media Relations
(919) 844-7100, x7195
SOURCE Encuity Research
Web Site: http://www.encuity.com
Posted: June 2012